Ekso Bionics Reports Third Quarter 2025 Financial Results

Core Viewpoint - Ekso Bionics Holdings, Inc. reported a revenue rebound and improved financial metrics for Q3 2025, indicating successful navigation through previous challenges and a focus on growth strategy while managing resources [3][10]. Financial Performance - For Q3 2025, the company recorded revenue of $4.2 million, a 2% increase year-over-year from $4.1 million in Q3 2024, and a 105% sequential increase from $2.1 million in Q2 2025 [3][10]. - Gross profit for Q3 2025 was $2.5 million, with a gross margin of approximately 60.3%, up from $2.2 million and 53.5% in Q3 2024, driven by higher margin Enterprise Health sales and lower device costs [4][10]. - Net loss for Q3 2025 was $1.4 million, or $0.54 per share, representing a 31% improvement from a net loss of $2.1 million, or $1.53 per share, in Q3 2024 [7][10]. Expense Management - Sales and marketing expenses decreased to $1.3 million in Q3 2025 from $1.8 million in Q3 2024, primarily due to lower payroll expenses related to the Employee Retention Credit [5]. - Research and development expenses were reduced to $0.6 million in Q3 2025 from $0.8 million in Q3 2024, also due to lower payroll expenses and headcount [6]. - General and administrative expenses decreased to $2.1 million in Q3 2025 from $2.3 million in Q3 2024, attributed to lower payroll expenses, partially offset by higher legal costs [7]. Strategic Initiatives - The company is exploring strategic transactions, which may include acquiring a business in a different industry or selling its current business, with no assurances that any transaction will occur [9][11]. - The company launched eksoUniversity and delivered its first official CEU certification to a physical therapist in Connecticut [10]. Cash Position - As of September 30, 2025, the company had cash of $2.7 million, down from $4.5 million at the end of 2024 [8][15]. Balance Sheet Overview - Total assets as of September 30, 2025, were $21.7 million, a decrease from $26.7 million at the end of 2024 [15]. - Total liabilities were $12.0 million, down from $13.9 million at the end of 2024, while stockholders' equity decreased to $9.7 million from $12.7 million [15].